Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1989-09-12
1991-10-22
Rollins, John W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 78, 514766, 424116, 424450, A61K 3170, A61K 31685, A61K 31015, A61K 3500
Patent
active
050595911
ABSTRACT:
Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.
REFERENCES:
patent: 3993754 (1976-11-01), Rahman et al.
patent: 4075324 (1978-02-01), Thizy et al.
patent: 4119724 (1978-10-01), Thizy et al.
patent: 4160827 (1979-07-01), Cho et al.
patent: 4256632 (1981-03-01), Levin et al.
patent: 4263428 (1981-04-01), Apple et al.
patent: 4271196 (1981-06-01), Schmidt
patent: 4272525 (1981-06-01), Wright
patent: 4287187 (1981-09-01), Hoeschele
patent: 4291023 (1981-09-01), Hoeschele et al.
patent: 4291027 (1981-09-01), Hoeschel et al.
patent: 4309420 (1982-01-01), Ghyczy et al.
patent: 4332795 (1982-06-01), Ghyczy et al.
patent: 4340599 (1982-07-01), Lieb et al.
patent: 4346084 (1982-08-01), Growdon et al.
patent: 4358442 (1982-11-01), Wirtz-Peitz
patent: 4372949 (1983-02-01), Kodama et al.
patent: 4396630 (1983-08-01), Riedl et al.
patent: 4397846 (1983-08-01), Weiner et al.
patent: 4411894 (1983-10-01), Schrank et al.
patent: 4419348 (1983-12-01), Rahman et al.
patent: 4430330 (1984-02-01), Growdon et al.
Schacht et al., 1983, "Aminoglycoside-Cell Receptor Interactions: Implications for Toxicity and In Vitro Models," Thirteenth International Congress of Chemotherapy.
Hokin, "Phospholipid Metabolism and Functional Activity of Nerve Cells", Structure and Function of Nervous Tissue, 1969, Bourne, ed., Academic Press, New York, vol. 3, pp.161-184.
Schact and Agranoff, "Phospholipid Labelling by [.sup.32 P]-Orthophosphate and [.sup.3 H]-Myo-Inositol in the Stimulated Goldfish Brain", J. Neurochem. 1972, vol. 19, pp. 1417-1421.
Margolis and Heller, "The Effect of Cholinergic and Other Pharmacological Agents on Brain Monophosphoinositide Turnover in Vivo", 1966, J. Pharmacol. Expt. Ther. 151:307-312.
Orsulakova et al., "Effect of Neomycin on Phosphoinositide Labelling and Calcium Binding in Guinea-Pig Inner Ear Tissues In Vivo and In Vitro", J. Neurochem., 1976, vol. 26, pp. 285-290.
Schibeci and Schacht, "Action of Neomycin on the Metabolism of Polyphosphoinositides in the Guinea Pig Kidney", Biochem. Pharmacol., 1977, 26:1769-1774.
Alexander et al., "Interaction of Aminoglycoside Antibiotics with Phospholipid Liposomes Studied by Microelectrophoresis", 1979, J. Antibiotics, 32:504-510.
Lodhi et al., "Ototoxicity of Aminoglycosides Correlated with Their Action on Monomolecular Films of Polyphosphoinositides", 1980, Biochem. Pharmacol, 29:597-601.
"The Pharmacological Basis of Therapeutics", 6th Edition, 1980, pp. 1233-1236, Goodman and Gilman, eds.
Medoff et al., "Antifungal Agents Useful in Therapy of Systemic Fungal Infections", 1983, Ann. Rev. Pharmacol. Toxicol. 23:303-330.
Bittman et al. (Readio & Bittman), "Equilibrium Binding of Amphotericin B and Its Methyl Ester and Borate Complex to Sterols", 1982, Biochim. Biophys. Acta, 685:219-224.
Taylor et al., "Amphotericin B in Liposomes: A Novel Therapy for Histoplasmosis", 1982, Ann. Rev. Respir. Dis. 125:610-611.
New et al., "Antileishmanial Activity of Amphotricin and Other Antifungal Antifungal Agents Entrapped in Liposomes", 1981, J. Antimicrob. Chemother. 8:371-381.
Goormaghtigh, et al., "Evidence of a Complex Between Adriamycin Derivatives and Cardiolipin: Possible Role in Cardiotoxicity", 1980, Biochm. Pharmacol. 29:3003-3010.
Goormaghtigh, et al., "Evidence of a Specific Complex Between Adriamycin and Negatively-Charged Phospholipids", 1980, Biochim. Biophys. Acta, 597:1-14.
Goormaghtigh, et al., "Adriamycin Inactivates Cytochrome C Oxidase by Exclusion of the Enzyme from Its Cardiolipin Essential Environment", Biochim. Biophys. Res. Comm., 1982, vol. 104(1), pp. 314-320.
Forssen and Tokes, "Improved Therpaeutic Benefits of Doxorubicin by Entrapment in Anionic Liposomes", 1983, Cancer Res., 43:546-550.
Louie and Bau, "Structure of [Pt(en)5'-CMP)].sub.2 2H.sub.2 O. An Example of Direct Platinum-Phosphate Bonding", 1977, J. Amer. Chem. Soc. 99:3874-76.
Goodgame et al., "Possible Mode of Action of Anti-Tumour Platinum Drugs: X-Ray Evidence for Cis Binding by Platinum of Two Inosine 5'-Monophosphate Molecules via the N(7) Positions", 1975, Biochim. Biophys. Acta., 378:153-157.
Bau et al., "Crystallographic Studies on Platinum-Nucleoside and Platinum-Nucleotide Complexes", 1977, J. Clin. Hematol. Oncol., Wadley Medical Bulletin, 7:51-61.
Davis and Abbitt, "Clinical Pharmacology of Antibacterial Drugs in the Uterus of the Mare", 1977, JAVMA 170(2):204-207.
Volanakis and Kaplan, "Specificity of C-Reactive Protein for Choline Phosphate Residues of Pneumococcal C-Polysaccharide (35323)", 1970, Proc. Soc. Exp. Biol. Med. 136:612-614.
Schacht, J., "Purification of Polyphosphoinositides by Chromatography on Immobilized Neomycin", 1978, J. Lipid Res. 19:1063-1067.
Nesmeyanova, et al., Chem. Abs. vol. 97:68366g, 1982.
Connors et al., Platinum Coordination Complexes in Cancer Chemotherapy, 1974.
Alving Carl R.
Fountain Michael W.
Janoff Andrew S.
Lenk Robert P.
Ostro Marc J.
Bloom Allen
Kurtz Catherine L.
Rollins John W.
The Liposome Company Inc.
LandOfFree
Drug preparations of reduced toxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug preparations of reduced toxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug preparations of reduced toxicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-108590